Immunovant, Inc. IMVT Cash Flow Statement
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| -$147.86M-33.6% | -$110.64M+12.5% | -$126.5M-4.9% | -$120.61M-13.3% | -$106.45M+4.2% | ||
| $96K-5.0% | $101K-3.8% | $105K-1.9% | $107K-1.8% | $109K+10.1% | ||
| $11.14M-12.4% | $12.72M-4.8% | $13.36M-27.8% | $18.51M+58.4% | $11.69M+0.3% | ||
| -$563K-76.5% | -$319K— | $0+100% | -$129K-51.8% | -$85K— | ||
| -$1.35M— | —— | -$1.07M+88.7% | -$9.4M— | —— | ||
| -$1.3M-3,524% | $38K+123% | -$167K-112% | $1.36M+598% | $195K— | ||
| -$4.31M-50.3% | -$2.87M-146% | -$1.16M-134% | -$498K-103% | $15.21M+190% | ||
| $26K+4.0% | $25K+4.2% | $24K0.0% | $24K+9.1% | $22K-4.3% | ||
| -$95.06M-3.0% | -$92.33M+9.9% | -$102.52M+12.7% | -$117.41M-6.1% | -$110.64M-10.2% | ||
| $8K— | $0— | $0— | $0-100% | $201K+11.7% | ||
| -$8K— | $0— | $0— | $0+100% | -$201K-11.7% | ||
| $0-100% | $516.68M+2,001% | $24.6M+743% | $2.92M-99.4% | $450M+31,880% | ||
| $3.64M-99.4% | $564.6M+2,196% | $24.6M+743% | $2.92M-99.4% | $450.61M+18,188% | ||
| -$988K-362% | $377K-57.1% | $878K+255% | -$566K— | —— | ||
| —— | $472.66M+714% | -$77.04M+33.0% | -$115.06M-134% | $339.29M+445% | ||
| —— | $1.64M— | —— | —— | $901K— | ||
| $96K-5.0% | $101K-3.8% | $105K-1.9% | $107K-1.8% | $109K+10.1% | ||
| -$1.35M— | —— | -$1.07M+88.7% | -$9.4M— | —— | ||
| —— | $756K-92.6% | $10.26M+293% | -$5.3M— | —— | ||
| -$4.31M-50.3% | -$2.87M-146% | -$1.16M-134% | -$498K-103% | $15.21M+190% | ||
| $26K+4.0% | $25K+4.2% | $24K0.0% | $24K+9.1% | $22K-4.3% | ||
| $126K0.0% | $126K0.0% | $126K0.0% | $126K-60.5% | $319K— | ||
| $18.25K0.0% | $18.25K0.0% | $18.25K0.0% | $18.25K-81.4% | $98K— | ||
| -$95.07M-3.0% | -$92.33M+9.9% | -$102.52M+12.7% | -$117.41M-5.9% | -$110.84M-10.2% | ||
| -$95.07M-3.0% | -$92.33M+9.9% | -$102.52M+12.7% | -$117.41M-5.9% | -$110.84M-10.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Immunovant, Inc. generate?
- Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.
- What is Immunovant, Inc.'s free cash flow?
- After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.
- Where does Immunovant, Inc.'s cash flow data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.